Abstract:To evaluate the impact of pathologic response of primary tumor on disease-free survival (DFS) and overall survival (OS) in patients with locally advanced breast cancer (LABC) and reached axillary pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). From January 2008 to June 2013, 210 patients who received NAC in Fudan University Shanghai Cancer Center and reached axillary pCR after operation were retrospectively analyzed regarding to the prognostic significance of achieving a pCR or not in primary tumor. Those patients were diagnosed as clinical stage II-III breast cancer and primary tumor and lymph nodes were confirmed by core needle biopsy before NAC. Clinical stage was assessed by physical examination and imaging procedures. Axillary lymph nodes and primary tumors response to NAC were assessed via histopathology after surgery. Axillary pCR was defined as no invasive lymph nodes were detected after axillary lymph nodes dissection or sentinel lymph node biopsy. No residual invasive carcinoma or only residual ductal carcinoma in situ (DCIS) in primary tumor tissue was considered as pCR in primary tumor. Patients were divided into two groups for statistical analysis, according to whether they reached pCR or not in primary tumor. The groups were compared in terms of DFS and OS. The median follow-up time was 35 months (range, 6-100 months). Median age of 210 patients was 50 years olds (range, 24-80 years old). 107 (51%) patients were hormone receptor positive and 72 (34.4%) of them were Her2 positive. All patients received NAC and 188 (89.5%) of whom received NAC based on paclitaxel and carboplatin, the median course was 4. 192 (91.4%) patients received postoperative chemotherapy and 151 (76.6%) patients received radiation therapy. Almost all hormone receptor positive patients (104/107) received hormone therapy and only 40.3% (29/72) Her2 positive patients received Herceptin therapy. Of all patients, 42.9% (90/210) reached pCR in primary tumor, who had favorable DFS compared with non-pCR ones (Hazard ratio: 0.4024, 95% confidence interval [CI] 0.1699-0.9530, P = 0.0658). OS didn’t show significant difference between two groups (HR: 0.2723, 95% [CI] 0.05391-1.3749, P = 0.2029). Postoperative radiation therapy significantly improved DFS in patients with residual tumor (HR: 0.2782, 95% [CI] 0.0777-0.9959, P = 0.0077), but didn’t improve OS (HR: 0.7971 95% [CI] 0.0719-8.8427, P = 0.8436). Because of relative low sample size in primary tumor pCR patients, radiation therapy improved neither DFS nor OS. Primary tumor pCR was a favorable factor for prognosis in patients who reached axillary pCR after NAC. Patients with residual tumor tend to have lower DFS compared with primary tumor pCR ones, but radiation therapy could improve DFS for them.

Is Pathologic Complete Response a Good Predictor for the Long-Term, Clinical Outcome in Patients with Gastric Cancer After Neoadjuvant Chemotherapy? A Retrospective, Multi-institution Study in China

Approaches and Genetic Determinants in Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer

Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer.

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Correlation of Pathological Complete Response with Survival after Neoadjuvant Chemotherapy in Gastric or Gastroesophageal Junction Cancer Treated with Radical Surgery: A Meta-Analysis.

Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes

Long-term Survival Outcomes of Advanced Gastric Cancer Patients Who Achieved a Pathological Complete Response with Neoadjuvant Chemotherapy: A Systematic Review of the Literature

Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection

Prediction of pathological complete response and prognosis in locally advanced rectal cancer

Impact of Pathological Response and Recurrence Pattern on the Survival of Patients Who Develop Recurrence from Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC).

The Impact of Pathological Response of Primary Tumor in Patients with Locally Advanced Breast Cancer Who Reached Axillary Pathological Complete Response (pcr) after Neoadjuvant Chemotherapy

Long-term survival outcome of locally advanced gastric cancer patients who achieved a pathological complete response to neoadjuvant chemotherapy

Role of CT in the Prediction of Pathological Complete Response in Gastric Cancer after Neoadjuvant Chemotherapy

A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer

Assessing the predictive value of clinical factors to pathological complete response for locally advanced rectal cancer: An analysis of 124 patients

[Significance and treatment strategies of pathologic complete response after neoadjuvant therapy for gastric cancer]

Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study

Survival analysis in patients with pathological complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy

Clinical Characteristics of Gastric Cancer Patients with Pathological Complete Response Following Neoadjuvant Chemotherapy: an Analysis of 11 Patients

[Factors Related with Pathological Complete Response of Neoadjuvant Chemotherapy in Primary Breast Cancer].

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis